SCHEDULE: Cormorant Asset Management Discloses 4% Stake in Praxis

Cormorant Asset Management and Bihua Chen report a 4% beneficial ownership stake in Praxis Precision Medicines, Inc. through a Schedule 13G filing.

Summary

• Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 1,000,000 shares of Common Stock in Praxis Precision Medicines, Inc.
• This ownership represents 4.00% of the company's outstanding Common Stock.
• The percentage is calculated based on 25,007,171 shares outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q.
• The reporting persons hold shared voting power and shared dispositive power over all 1,000,000 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional ownership stake by a reputable investment firm is generally viewed as a positive indicator of investor confidence, although the filing itself does not provide operational or financial performance details.

Positives

• A significant 4.00% stake by an institutional investor like Cormorant Asset Management can signal confidence in Praxis Precision Medicines, Inc.'s future prospects.
• The filing indicates the investment is for ordinary course of business, not for control, suggesting a passive investment interest.

Risks

• The filing itself does not detail company-specific operational or financial risks. It is a disclosure of ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

The disclosure of a 4% stake by a specialized healthcare investment firm like Cormorant Asset Management in a precision medicine company like Praxis could be viewed as a positive signal within the biotechnology and pharmaceutical sectors, indicating potential value or strategic interest in the company's pipeline or market position.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership, common for institutional investors acquiring significant stakes in publicly traded companies. It does not provide performance metrics for comparison.
• Cormorant Asset Management is a known investor in the life sciences sector, and their investment in Praxis Precision Medicines aligns with their typical investment focus on innovative biotechnology companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance investor confidence and potentially influence stock liquidity and valuation.
• Employees, Customers, Suppliers, Creditors: This filing primarily concerns ownership structure and does not directly impact these stakeholders in the short term, though sustained institutional interest can indirectly support company stability and growth.

Next Steps

• The reporting persons will be required to file further amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if their investment intent changes from passive to active.

Key Dates

Keywords

Praxis Precision Medicines, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals